Navigation Links
Top-line Data Show AcelRx Pharmaceuticals' ARX-04 Achieves Primary Endpoint in Dose-Finding Phase 2 Clinical Trial
Date:4/24/2013

REDWOOD CITY, Calif., April 24, 2013 /PRNewswire/ --- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced top-line results demonstrating that a placebo-controlled, dose-finding, Phase 2 study of its investigational single-dose sublingual sufentanil NanoTab for acute pain, ARX-04, successfully met its primary endpoint.  Results demonstrated that patients receiving 30 mcg sufentanil NanoTab doses, administered by a healthcare professional, no more frequently than once per hour, had significantly greater pain reduction as measured by Summed Pain Intensity Difference to baseline during the 12-hour study period (SPID-12) than placebo-treated patients (p=0.003).  Adverse events reported in the study were generally mild-to-moderate in nature, with two serious adverse events of post-surgical infection reported, both of which were determined by the investigator to be unrelated to study drug.  Two patients dropped out of the study due to adverse events, one patient's discontinuation considered unrelated to study drug, and the other considered probably related to study drug, both in the 30 mcg-treated group.

"The goal of this program, to find an effective sublingual sufentanil dose that could be administered less frequently by a healthcare professional than our patient-administered ARX-01 product candidate, has been met", said Dr. Pamela Palmer , Chief Medical Officer, AcelRx Pharmaceuticals.  "There is a need for a non-invasive, rapid-onset strong analgesic to provide short-term treatment of pain for the wounded soldier on the battlefield, the trauma victim at the site of a road-traffic accident, the migraine patient in the emergency room, or in g
'/>"/>

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sinovac EV71 Vaccine Phase III Top-Line Results Presented at 13th Annual World Vaccine Congress & Expo
2. AstraZeneca Announces Top-Line Results From OSKIRA-1 Phase 3 Study of Fostamatinib in Rheumatoid Arthritis
3. Merrimack Pharmaceuticals Announces Top-Line Results From A Single Arm Phase 2 Advanced Lung Cancer Study In Patients With Resistance To An Anti-EGFR Tyrosine Kinase Inhibitor
4. AcelRx Top-line Data Show Primary Endpoint Achieved in Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Post-Operative Pain in Major Open Abdominal Surgery Patients
5. Intra-Cellular Therapies Announces Completion of Phase I Single Rising Dose Trial of First-in-Class Selective Phosphodiesterase 1 (PDE1) Inhibitor and Reports Top-line Safety and Pharmacokinetic Findings
6. AstraZeneca Announces Top-Line Results of OSKIRA-4 Phase IIb Study of Fostamatinib as a Monotherapy for Rheumatoid Arthritis
7. AcelRx Announces Achievement of the Primary End-Point in Phase 3 Comparative Study Involving the Sufentanil NanoTab PCA System and Plans to Hold a Conference Call and Webcast Tomorrow to Discuss Top-Line Results
8. Vermillion Announces Positive Top-Line Results from the OVA500 Multi-Center Study Led by UC Irvine
9. Top-line Data From Phase 3 Trial of Ataluren in Patients with Nonsense Mutation Cystic Fibrosis Show Promising Results
10. Amgen Announces Top-Line Results Of Phase 3 Sensipar®/Mimpara® EVOLVE™ Trial
11. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... RIDGE, N.J. , Oct. 22, 2014 /PRNewswire/ ... (RMANJ), a world-renowned leader in the field of ... rapid approach to embryonic screening. The research abstract, ... Society for Reproductive Medicine (ASRM) meeting in ... screening (CCS) and single gene defect (SGD) pre-implantation ...
(Date:10/22/2014)... ATLANTA , Oct. 22, 2014  CryoLife, Inc. ... and tissue processing company focused on cardiac and vascular ... , President and Chief Executive Officer, has been elected ... 2014. Steven G. Anderson , Executive ... Pat has proven to be an excellent leader who ...
(Date:10/22/2014)... Calif., Oct. 21, 2014 Abaxis, Inc. (NasdaqGS: ... point-of-care blood analysis systems, today reported financial results for ... Second quarter overview: , Revenues of $53.9 ... , Diluted EPS of $0.24, up 33% over last ... Service revenues from Abaxis Veterinary Reference Laboratories (AVRL) of ...
Breaking Medicine Technology:New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 2New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 3Pat Mackin Joins CryoLife Board of Directors 2Pat Mackin Joins CryoLife Board of Directors 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 5Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 6Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 7Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 8Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 9Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 10Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 11Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 12Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 13Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 14
... , PHOENIX , Feb. ... selected SCAN Health Plan Arizona as their Medicare Advantage Plan (MAPD) ... to join SCAN until March 31, 2010 . , ... is affiliated with more than 6,800 physician locations as well as ...
... , SAN DIEGO , Feb. 9 ... manufacturer of precision intravascular therapy guidance tools designed to enhance ... announced today that it has received 510(k) clearance from the ... Eye® Platinum digital IVUS catheter in the United States ...
Cached Medicine Technology:SCAN Health Plan Arizona Exceeds Expectations as Local Seniors Select Medicare Advantage Coverage 2SCAN Health Plan Arizona Exceeds Expectations as Local Seniors Select Medicare Advantage Coverage 3Volcano Receives FDA Clearance to Market the Eagle Eye(R) Platinum Digital IVUS Catheter 2Volcano Receives FDA Clearance to Market the Eagle Eye(R) Platinum Digital IVUS Catheter 3Volcano Receives FDA Clearance to Market the Eagle Eye(R) Platinum Digital IVUS Catheter 4
(Date:10/25/2014)... (PRWEB) October 25, 2014 QueenBeeTickets.com has ... a great selection at affordable prices. Bob Seger & ... Huntington Center and Nationwide Arena are going on sale ... Click Here to browse the selection of ... at QueenBeeTickets.com. , The famous singer is touring North ...
(Date:10/25/2014)... FRIDAY, Oct. 24, 2014 (HealthDay News) -- Interrupting blood supply ... help reduce the risks associated with the surgery, according to ... to stop the blood supply to the heart to be ... blood, the heart will reduce its ability to produce energy ... blood flow to another large muscle, such as an arm ...
(Date:10/25/2014)... Oct. 23, 2014 (HealthDay News) -- Current osteoporosis ... younger postmenopausal women at risk for osteoporosis-related fractures, ... to prevent fractures, we need tools that help ... injuries so that we can target these at-risk ... Crandall, professor of medicine in the division of ...
(Date:10/22/2014)... On October 22, CBS will air an episode ... fictional and real. The Charles E Holman Morgellons ... advocacy and philanthropy in the battle against Morgellons Disease, ... impart truth and clarity about this misunderstood and routinely ... about Morgellons Disease (MD) and most people ...
(Date:10/22/2014)... TUESDAY, Oct. 21, 2014 (HealthDay News) -- The ... passengers arriving from Ebola-affected nations of West Africa ... screen them for infection with the virus. ... Jeh Johnson noted that 94 percent of air ... land at one of these five airports -- ...
Breaking Medicine News(10 mins):Health News:QueenBeeTickets.com Features Bob Seger & The Silver Bullet Band Tickets for Charleston Civic Center, Huntington Center, and Nationwide Arena at Reduced Prices 2Health News:Brief Interruption of Blood Supply to Limb Might Aid Heart Surgery: Study 2Health News:Osteoporosis Screening Guidelines May Miss Younger Women at Risk 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3
... the secure,remote service and support company today announced ... MCK ), has selected,the Axeda(R) ServiceLink solution ... which ensure safety and accuracy throughout the,medication use ... Axeda(R) Software Management,application will be used to remotely ...
... mission-critical outsourcing to Brooke Army Medical Center, ... SINT ), an information technology and network ... a new competitive task order under,the US Army,s ... Personnel Service and Support to provide,services to Brooke ...
... CHARLES TOWN, W.Va., Oct. 16 ReBuilder,Medical Technologies, ... agreed upon a Joint Venture with UFFE Medical, ... ReBuilder Medical,s unique home treatment for,the skin disease ... sometimes hundreds of pimple-like lesions that can take ...
... has been named one of 10 new centers in ... make critical treatment decisions about therapeutic products and interventions. ... for Healthcare Research and Quality,s Center for Education and ... and test systems to optimize drug choice, monitoring and ...
... Today, the International Association for the Study of Pain (IASP) ... to draw attention to the significant impact of chronic pain ... Lack of awareness of pain issues affecting women and ... of millions of women. , Chronic pain affects a ...
... Discovery could lead to new therapies , TUESDAY, Oct. 16 ... cancer has been identified. The finding about the Dmp1 ... at the cellular level to cause lung cancer. , The ... of human non-small-cell lung cancers and found that the ...
Cached Medicine News:Health News:Axeda Selected for Remote Monitoring and Service of Automation Technologies 2Health News:SI International Awarded $4 Million Army HRsolutions Task Order 2Health News:SI International Awarded $4 Million Army HRsolutions Task Order 3Health News:ReBuilder Medical Technologies, Inc. Announces UK Demand for Safe Molluscum Contagiosum Treatment Leads to Distribution Agreement with UFFE Medical, LTD. Expected 10% Sales Increase. 2Health News:ReBuilder Medical Technologies, Inc. Announces UK Demand for Safe Molluscum Contagiosum Treatment Leads to Distribution Agreement with UFFE Medical, LTD. Expected 10% Sales Increase. 3Health News:New UIC center to study drug choices, safety 2Health News:IASP declares the Global Year Against Pain in Women 2Health News:IASP declares the Global Year Against Pain in Women 3Health News:Researchers ID New Gene Linked to Lung Cancer 2
... Ureteral Stents have all the advantages ... addition, a unique 360 degree kidney ... placement in the renal pelvis or ... remarkably comfortable stent, ideal for use ...
All the advantages of Dr. Roy P. Finney's classic stent design with an open tip....
This EIA microplate opens new perspectives in the direct detection of Chlamydia. The choice of microplate immunoenzymatic technology and the use of a monoclonal antibody result in a combination of c...
Inquire...
Medicine Products: